Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee

NCT04124042 is registered in ClinicalTrials.gov with Xalud Therapeutics, Inc. as lead sponsor.

NCT NCT04124042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04124042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
Lead sponsor
Xalud Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2020
Completion date
April 26, 2022
Enrollment
289 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee